Biocon has been granted a patent for a humanized IgG1 antibody that targets CD6 on various cell types. The antibody, named T1h, binds to the SRCR domain 1 of CD6. The patent claim specifies the VH and VK sequences for the monoclonal antibody. GlobalData’s report on Biocon gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Biocon, Hormone-based therapies for metabolic disorders was a key innovation area identified from patents. Biocon's grant share as of May 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Humanized igg1 antibody binding to human cd6
A recently granted patent (Publication Number: US11981743B2) discloses a humanized IgG1 monoclonal antibody designed to target human CD6. The antibody consists of specific heavy and light chain variable sequences, as detailed in the patent claims.
The patent also outlines various methods of treatment using the humanized IgG1 monoclonal antibody, particularly focusing on inhibiting T cell proliferation in patients with conditions such as graft-versus-host disease, transplant rejection, psoriasis, rheumatoid arthritis, type-1 diabetes, cutaneous T cell lymphoma, thyroiditis, and autoimmune encephalomyelitis. The antibody shows potential for treating a range of diseases and disorders, highlighting its versatility and therapeutic applications in various medical conditions.
To know more about GlobalData’s detailed insights on Biocon, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.